By Professor Richard Bryan Lock

Journal articles

LaRocca RV; Lock RB, 1998, 'Surveying the frontiers of cancer research and therapy', Louisville Medicine, 45, pp. 511 - 513

Lock RB; Thompson BS; Sullivan DM; Stribinskiene L, 1997, 'Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation', Cancer Chemother Pharmacol, 39, pp. 399 - 409

Lock RB; Thompson BS; Stribinskiene L, 1996, 'Differential ability of 2,4-dinitrophenol to modulate etoposide cytotoxicity in mammalian tumor cell lines associated with inhibition of macromolecular synthesis', Int J Oncology, 8, pp. 305 - 311

Lock RB; Stribinskiene L, 1996, 'Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival', Cancer Research, 56, pp. 4006 - 4012

Sullivan DM; Feldhoff PW; Lock RB, 1995, 'Characterization of an altered DNA topoisomerase IIα from a mitoxantrone resistant mammalian cell line which is hypersensitive to DNA crosslinking agents', Int J Oncology, 7, pp. 1383 - 1393

Eastman A; Grant S; Lock R; Tritton T; Van Houten N; Yuan J, 1994, 'Cell Death in Cancer and Development', Cancer Research, 54, pp. 2812 - 2818

Lock RB; Galperina OV; Feldhoff RC; Rhodes LJ, 1994, 'Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells', Cancer Research, 54, pp. 4933 - 4939

Lock RB; Keeling PK, 1993, 'Responses of HeLa and Chinese hamster ovary p34cdc2/cyclin-B kinase in relation to cell cycle perturbations induced by etoposide', Int J Oncology, 3, pp. 33 - 42

Lock RB, 1992, 'Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide', Cancer Research, 52, pp. 1817 - 1822

Webb CD; Latham MD; Lock RB; Sullivan MD, 1991, 'Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line', Cancer Research, 51, pp. 6543 - 6549

Lock RB; Ross WE, 1990, 'Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells', Cancer Research, 50, pp. 3761 - 3766

Lock RB; Ross WE, 1990, 'Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells', Cancer Research, 50, pp. 3767 - 3771

Shen J-W; Subjeck JR; Lock RB; Ross WE, 1989, 'Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response', Mol Cell Biol, 9, pp. 3284 - 3291

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: Differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', NCI Monographs, pp. 177 - 181

Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RPEA, 1988, 'Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I', Cancer Research, 48, pp. 6404 - 6410

Lock RB; Hill BT, 1988, 'Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines', Int J Cancer, 42, pp. 373 - 381

Hill BT; Whelan RDH; Hosking LK; Shellard SA; Bedford P; Lock RB, 1988, 'Interactions between antitumor drugs and radiation in mammalian tumor cell lines: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro', NCI Monographs, 6, pp. 171 - 181

Hill BT; Whelan RDH; Bellamy AS; Lock RB, 1988, 'The differential expression of drug resistance or collateral sensitivity in a continuous human tumor cell line established from a squamous cell carcinoma of the tongue following in vitro exposure to fractionated X-irradiation', , pp. 167 - 173

Lock RB; Ross WE, 1987, 'DNA topoisomerases in cancer therapy', Anti-Cancer Drug Design, 2, pp. 151 - 164

Bellamy AS; Whelan RDH; Lock RB; Hill BT, 1987, 'Effects of fractionated X-irradiation on subsequent response to acute X-irradiation in two human tumour cell lines in vitro', Int J Radiat Biol, 51, pp. 681 - 691

LOCK RB; HILL BT, 1986, 'DRUG-RESISTANCE INVITRO - INTERACTIONS BETWEEN X-IRRADIATION, ETOPOSIDE AND VINCRISTINE', BIOCHEMICAL SOCIETY TRANSACTIONS, 14, pp. 618 - 619, http://dx.doi.org/10.1042/bst0140618

Conference Papers

Lock RB; Evans K; Randall J; Erickson SW; Earley EJ; Neuhauser S; Stearns T; Philip V; Teicher BA; Watkins K; Sloss CM; Zweidler-McKay PA; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 8983 - 8984, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-159867

Lock RB; Evans K; Watts B; Randall J; Toscan CE; Earley EJ; Erickson SW; Belmontes B; Wong P; Teicher BA; Hughes PE; Smith MA, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 11690 - 11691, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-159885

Connerty P; Moles E; deBock C; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB, 2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-21-P143

Lock RB; Evans K; El-Zein N; Lannutti BJ; Jessen KA; Earley EJ; Erickson SW; Smith MA; Kurmasheva R; Houghton PJ, 2021, 'Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)', in Cancer Research, American Association for Cancer Research (AACR), pp. 3038 - 3038, http://dx.doi.org/10.1158/1538-7445.am2021-3038

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Smith MA, 2021, 'Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3039 - 3039, http://dx.doi.org/10.1158/1538-7445.am2021-3039

Lock RB; Evans K; El-Zein N; Earley EJ; Erickson SW; Teicher BA; Sung V; Smith MA, 2021, 'Abstract LB171: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)', in Cancer Research, American Association for Cancer Research (AACR), pp. LB171 - LB171, http://dx.doi.org/10.1158/1538-7445.am2021-lb171

Fleuren E; Dolman E; Lau L; Xie J; Batey D; Mayoh C; Barahona P; Khuong Quang DA; Wong M; ZERO PDTT; ZERO OT; Norris M; Haber M; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Lock R; Ekert P, 2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting, Virtual, 24 June 2021

Lock RB; Evans K; Jones CD; Erickson SW; Teicher BA; Unger TJ; Landesman Y; Smith MA, 2020, 'The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4181

Li J; Troche C; Zhang JH; Shrimp J; Roth JS; Jing D; Swaroop A; Kulis M; Oyer J; Will C; Dupere-Richer D; Riva A; Pipe C; Sobn A; Norton S; Bennett RL; Shen M; Hall MD; Lock RB; Licht JD, 2019, 'A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-126910

Lock RB; Evans K; Jones CD; El-Zein N; Bendak K; Toscan CE; Mayoh C; Erickson SW; Teicher BA; Smith MA, 2019, 'Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123867

Lock RB; Toscan CE; Jing D; Mayoh C, 2019, 'Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. a123 - a123, http://dx.doi.org/10.1158/1535-7163.targ-19-a123

Lock RB; Evans K; Jones CD; El-Zein N; Erickson SW; Beaussant-Cohen S; Kelley EL; Teicher BA; Smith MA, 2019, 'The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-19-C004

Fleuren E; Xie J; Barahona P; Sherstyuk A; Batey D; Jin Yi L; Lau L; Khuong Quang DA; Failes T; Chow S-O; Mayoh C; Wong M; Kumar A; ZERO OT; ZERO PDTT; ZERO SMT; Thomas D; Trahair T; Haber M; Mould E; Lock R; Ziegler D; Tyrrell V; Cowley M; Ekert P, 2019, 'Personalised medicine for high-risk paediatric and AYA sarcoma patients', Tokyo, Japan, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, 13 November 2019, https://www.ctos.org/Portals/0/PDF/2019%20CTOS%20Final%20Program.pdf

Fleuren E; Lau L; Barahona P; Sherstyuk A; Mayoh C; Khuong Quang DA; Wong M; Xie J; Batey D; Grebert-Wade D; Strong P; Lim JL; Chow S-O; Kumar A; Failes T; Arndt G; Mould E; Haber M; Lock R; Trahair T; Marshall G; Ziegler D; Tyrrell V; Cowley M; Ekert P, 2019, 'Precision medicine for high-risk paediatric and AYA sarcomas', Sydney, presented at Kids Cancer Alliance - Annual Meeting, Sydney, 31 October 2019, https://kca.org.au/wp-content/uploads/2019/11/2019-ECR-and-Student-Event-Program.pdf

Teicher BA; Lock RB; Evans K; Houghton PJ; Kurmasheva RT; Gorlicki R; Erickson S; Wishka D; Morris J; Difilippantonio M; Collins JE; Smith MA; Doroshow JH, 2019, 'Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. 3839 - 3839, http://dx.doi.org/10.1158/1538-7445.am2019-3839

Earley E; Gorlick R; Houghton PJ; Maris JM; Li X-N; Lock RB; Teicher B; Smith MA; Erickson SW, 2019, 'Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-321

Earley E; Gorlick R; Houghton PJ; Mans JM; Li X-N; Lock RB; Teicher B; Smith MA; Erickson SW, 2019, 'Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-LB-321

Lock RB; Evans K; Pritchard T; Toscan C; Mayoh C; Teicher B; Kurmasheva RT; Houghton PJ; Smith M, 2018, 'A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, presented at 60th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 01 December 2018 - 04 December 2018, http://dx.doi.org/10.1182/blood-2018-99-113207

Jing D; Huang Y; Liu X; Sia K; Poulos RC; Span M; Zhang C; Mi J; Wong JWH; Beck D; Pimanda JE; Lock RB, 2018, 'Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3173

Lock RB; Evans K; Pritchard T; Erickson SW; Guo Y; Claremon DA; McGeehan GM; Teicher BA; Smith MA, 2018, 'Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3187

Teicher BA; Lock RB; Collins JM; Gorlick R; Kolb EA; Houghton PJ; Kurmasheva RT; Li X-N; Erickson SW; Guo Y; Evans K; Qi L; Smith MA, 2018, 'Pediatric Preclinical Testing Consortium evaluation of 4 '-thio-2 '-deoxycytidine (TdCyd) and 5-aza-4 '-thio-2 '-deoxycytidine (Aza-TdCyd)', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B12

Krytska K; Evans K; Pritchard T; Tsang M; Yung R; Mosse YP; Erickson SW; Guo Y; Baloglu E; Landesman Y; Jensen KA; Senapedis W; Teicher BA; Smith MA; Lock RB; Maris JM, 2018, 'Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B14

Lock RB; Evans K; Yung R; Pritchard T; Teicher BA; Duan J; Guo Y; Erickson SW; Smith MA, 2018, 'The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B16

Wakefield C; Quinn V; Doolan E; Fardell J; Tucker K; Patenaude A; Marshall K; Lock R; Signorelli C; Georgiou G; Cohn R, 2017, 'The use of Murine Models of Chemosensitivity to Anticancer Agents in Childhood Cancer Clinical Care: Survivor, Parent and Community Acceptability and Willingness-to-Pay', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S60 - S61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408978201113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Somers K; Middlemiss S; Biktasova A; Karsa M; Cheung L; Kosciolek A; Evans K; Mayoh C; Kees UR; Korotchkina L; Chernova OB; Lock RB; Gudkov AV; Haber M; Norris MD; Henderson MJ, 2017, 'Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1175

Evans K; Pritchard T; Henderson MJ; Somers K; Karsa M; Cheung L; Yung R; Erickson SW; Korotchkina L; Chernova O; Gudkov A; Smith MA; Lock RB, 2017, 'The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1942

Li KL; Bray SC; Iarossi D; Adams J; Zhong L; Noll B; Rahaman MH; Richmond J; To LB; Lewis ID; Lock RB; Wang S; D'Andrea RJ, 2015, 'Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.1365.1365

Smith MA; Kang M; Reynolds PC; Lock RB; Carol H; Gorlick R; Kolb AE; Maris JM; Keir ST; Billups CA; Kurmasheva R; Houghton PJ, 2015, 'Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)', in Cancer Research, American Association for Cancer Research (AACR), PA, Philadelphia, pp. 1615 - 1615, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.am2015-1615

Jones L; Richmond J; Evans K; Lock RB, 2015, 'Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1631

Back to profile page